Stock Strategist Industry Reports

These companies have underperformed the industry, but we see years of solid growth ahead.

Wind and solar generation will drive the U.S. economy's decarbonization plan.

Podcasts, connected TVs, and e-commerce platforms will help grow digital ad spending.

We don't think so. In fact, we think driver demographics bode well for auto sales.

Despite the massive disruption, we still see opportunities across some affected sectors.

Growth is priced into most valuations, but the top advertisers still have our attention.

Expanded insurance rolls would be good news for the managed-care organizations and service providers we cover.

A look at the firms that offer long-term growth upside.

Hopes for eradication fade, further highlighting the benefits of vaccination and boosters.

As we incorporate ESG factors into our analysis, we see a manageable headwind.

They may have a sunny outlook, but they trade above what we think they're worth.

It's close, but some industries are still recovering.

Moats and management make the difference.

We think the worst of the damage was in the second quarter.

Once the vehicle shortage is resolved, inflation should be back on trend.

Interest rates will be one of the biggest drivers and the biggest question that investors need to think about when they’re considering investing.

The market is warm to the idea, but we don't see a meaningful long-term impact for companies in this space.

Firms may face headwinds in U.S. sales, but our fair value estimates haven't budged.

We focus on quality companies in an environment where investors are engaging in rank speculation.

Institutions and students bear the brunt, but opportunities are considerable.

Capital returns are coming back, but don't forget about valuations.

The market’s optimistic valuation for Airbnb is tough to accommodate.

But investors can still find value in U.S. cannabis stocks.

Innovations in spinal cord stimulation bolster moats at Medtronic, Boston Scientific, and Abbott.

Robust e-commerce sales by traditional retailers during the COVID-19 pandemic create a lasting role for physical stores.

Supply-side pressures are behind our increase for this year.

We expect a mid-single-digit impact to average U.S. equity valuations.

We think the cloud holds substantial--and underestimated--opportunity for some of these companies.

The semiconductor space is a constant battle against commoditization.

The global COVID-19 vaccine market is currently dominated by mRNA firms, but competitors are gaining strength.

Limited vaccine supply in other countries could make global immunity tougher to achieve, though.

Here's how regulation can dictate their growth and valuation.

But more-affordable homes will be needed to realize millennials' ownership potential.

We've increased our U.S. GDP growth forecast.

We think the market misunderstands the ramifications of e-commerce.

A look at the automakers and suppliers that are best positioned to benefit from the industry's recovery.

Competition presents headwinds to players in the travel market, however.

It's been left behind in the runup in energy prices, and here's why.

But more dots move toward a rate hike--or hikes--in 2022 or 2023.

We think Marriott and Hilton are the best positioned.

Productive capacity, not stimulus, is what drives the economy’s long-term potential GDP.

Despite stubbornly high unemployment, we have reason to believe fiscal stimulus has helped household finances hold up across all income levels.

Lockdowns and next-generation consoles are supercharging growth.

The U.S. economic recovery paused at the end of 2020, but it will soon be ready for liftoff.

We see the best values in high-quality gas utilities.

If liquid biopsy lives up to its potential, a paradigm shift in cancer detection is possible.

High yields indicate opportunity as the probability of cuts is low.

We see strong growth and reduced cyclicality for the industry.

The sector's expensive overall, and some valuations are downright alarming.

However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.